Management of mantle cell lymphoma in fit, younger adults

This algorithm describes management of stage II-IV MCL in patients who are suitable for autologous HCT; refer to related UTD topic for management of asymptomatic patients with non-nodal MCL (eg, leukemic, non-nodal MCL or involvement of gastrointestinal tract-only), stage I MCL, and patients who are not suitable for transplantation. Eligibility for autologous HCT generally requires age <65 years without major organ dysfunction. Refer to related UpToDate material for details of diagnosis, staging, eligibility for transplantation, and treatment of MCL.